Posted by Michael Wonder on 19 Nov 2018
Pharma ignores the squabbling and prepares for a hard Brexit
19 November 2018 - Costs are irrecoverable in industry that has to plan for all possible scenarios.
At Japanese pharma company Eisai’s European headquarters, a warehouse is piled to its 15 metre high rafters with tablets and ingredients for medicines that will eventually be exported to 70 countries.
But whatever is left in four months will have to be thrown away. After Britain leaves the European Union on March 29, these supplies will be “non-compliant” with EU licences and rules that mean medicines destined for patients in mainland Europe must be released and safety-tested from one of the 27 remaining member states.
